Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NGcGM3 ganglioside
- Molecular classification
- Glycosphingolipid, Ganglioside, Tumor-associated antigen
01
Overview
NGcGM3 ganglioside is a glycosphingolipid expressed in various human cancers but absent in normal human tissues. Its selective expression makes it a valuable target for cancer immunotherapy approaches, including antibodies, vaccines, and CAR T-cell therapies. It is considered a tumor-associated antigen and a negative prognostic marker in several cancers.
- Other names
- GM3(Neu5Gc)N-glycolylneuraminic acid-containing GM3
02
Mechanism of action
Racotumomab and mAb 14F7 bind to NGcGM3 on tumor cells, leading to antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct induction of apoptosis. CAR T cells engineered to target NGcGM3 directly kill tumor cells.
03
Biological functions
Immune suppressionTumor cell survivalCell membrane integrity
04
Disease associations
Cancer
05
Safety considerations
Potential for off-target effects on normal tissues if NGcGM3 expression is induced or present at low levels due to dietary intake or other factors.Immunogenicity of vaccinesCytokine Release Syndrome (CRS) and other toxicities associated with CAR T-cell therapy.
06
Interacting drugs
Racotumomab
2 more in the full profile.
07
Biomarkers
NGcGM3 expression level in tumor tissue
Beyond the preview
Go deeper on NGcGM3 ganglioside.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGcGM3 ganglioside.